Tumor Biology

, Volume 37, Issue 12, pp 16029–16038 | Cite as

Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with I–IIIA non-small cell lung cancer

  • Xuan Hong
  • Zhaoyang Yang
  • Meng Wang
  • Li Wang
  • Qingyong Xu
Original Article
First Online:
Received:
Accepted:
  • 152 Downloads

Abstract

Decorin, chiefly synthesized by tumor stroma, is known as a tumor suppressor. However, the clinical and prognostic significance in lung cancer remained unclear. Here, decorin and Ki67 expression was detected by immunohistochemistry (IHC) in I–IIIA non-small cell lung cancer (NSCLC) tissues (n = 264) in comparison to adjacent normal tissues (n = 40). The relationship between the expression of decorin and clinical characteristics, as well as Ki67 index and prognosis, was analyzed. Decorin expression was decreased in both the stroma (P < 0.001) and the tumor cells (P = 0.038) in NSCLC specimens. There was the lowest stromal expression of decorin in patients with G3 adenocarcinoma and higher Ki67 index in the stromal decorin-negative group. The Kaplan–Meier survival analysis demonstrated that lack of decorin in the stroma was correlated with a shorter DFS and OS (P = 0.005 and P = 0.010, respectively), while there was no significant association between decorin expression in the tumor cells and outcome. Multivariate analysis showed that reduced expression of decorin in the stroma was an independent prognostic factor for poor outcome including DFS (HR = 5.685, 95 % CI 0.493–0.933; P = 0.017) and OS (HR = 6.579, 95 % CI 0.484–0.908; P = 0.010). Negative decorin in the stroma combined with high Ki67 index predicted poorer outcomes for I–IIIA NSCLC patients. Our results provide data on decorin expression in both the stroma and cancer cells in NSCLC and reveal that reduced expression of stromal decorin correlates with high Ki67 index and has prognostic significance for poor outcome in I–IIIA NSCLC. Our data suggest that evaluating stromal decorin expression might be useful in assessing the prognosis and malignant potential.

Keywords

Decorin Ki67 Non-small cell lung cancer Immunohistochemistry Prognosis 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This study was funded by the Natural Science Foundation of Heilongjiang Province (D201154), the Heilongjiang Postdoctoral Science Foundation (LRB2010-378), and the Health Department Foundation of Heilongjiang Province (No. 2011-125).

Compliance with ethical standards

This study was approved by the ethical committee of Harbin Medical University Cancer Hospital. Informed consent was obtained from all individual participants included in this study. All procedures in this study involving human participants were in accordance with the ethical standards of the local research committee and with the 1964 Helsinki Declaration and its later amendments of comparable ethical standards.

Conflicts of interest

None.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2011, National Cancer Institute. Bethesda, MD: National Cancer Institute; 2014. Available at: http://seer.cancer.gov/csr/1975_2011/. Accessed 5 Feb 2016.
  4. 4.
    Mok TS, YL W, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.CrossRefPubMedGoogle Scholar
  5. 5.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gandellini P, Andriani F, Merlino G, D'Aiuto F, Roz L, Callari M. Complexity in the tumour microenvironment: cancer associated fibroblast gene expression patterns identify both common and unique features of tumour-stroma crosstalk across cancer types. Semin Cancer Biol. 2015;35:96–106.Google Scholar
  8. 8.
    Goldoni S, Iozzo RV. Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer. 2008;123:2473–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Neill T, Schaefer L, Iozzo RV. Decorin: a guardian from the matrix. Am J Pathol. 2012;181:380–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Sofeu Feugaing DD, Götte M, Viola M. More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol. 2013;92:1–11.CrossRefPubMedGoogle Scholar
  11. 11.
    McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res. 2002;8:1127–38.PubMedGoogle Scholar
  12. 12.
    Qian Q, Shi X, Lei Z, Zhan L, Liu RY, Zhao J, Yang B, Liu Z, Zhang HT. Methylated +58CpG site decreases DCN mRNA expression and enhances TGF-β/Smad signaling in NSCLC cells with high metastatic potential. Int J Oncol. 2014;44:874–82.PubMedGoogle Scholar
  13. 13.
    Shi X, Liang W, Yang W, Xia R, Song Y. Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation andmetastasis. Tumour Biol. 2015;36:3345–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Biaoxue R, Xiguang C, Hua L, Hui M, Shuanying Y, Wei Z, Wenli S, Jie D. Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers. 2011;26:9–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Bi X, Pohl NM, Qian Z, Yang GR, Gou Y, Guzman G, Kajdacsy-Balla A, Iozzo RV, Yang W. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis. 2012;33:326–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Van Bockstal M, Lambein K, Gevaert O, De Wever O, Praet M, Cocquyt V, Van den Broecke R, Braems G, Denys H, Libbrecht L. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast. Histopathology. 2013;63:520–33.PubMedGoogle Scholar
  17. 17.
    Boström P, Sainio A, Kakko T, Savontaus M, Söderström M, Järveläinen H. Localization of decorin gene expression in normal human breast tissue and in benign and malignant tumors of the human breast. Histochem Cell Biol. 2013;139:161–71.CrossRefPubMedGoogle Scholar
  18. 18.
    Henke A, Grace OC, Ashley GR, Stewart GD, Riddick AC, Yeun H, O'Donnell M, Anderson RA, Thomson AA. Stromal expression of decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in developing prostate and decreased levels of decorin in prostate cancer. PLoS One. 2012;7:e42516.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bozoky B, Savchenko A, Guven H, Ponten F, Klein G, Szekely L. Decreased decorin expression in the tumor microenvironment. Cancer Med. 2014;3:485–91.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Sainio A, Nyman M, Lund R, Vuorikoski S, Boström P, Laato M, Boström PJ, Järveläinen H. Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies. PLoS One. 2013;8:e76190.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Köninger J, Giese NA, di Mola FF, Berberat P, Giese T, Esposito I, Bachem MG, Büchler MW, Friess H. Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation ofchemotherapeutic action. Clin Cancer Res. 2004;10:4776–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Nyman MC, Sainio AO, Pennanen MM, Lund RJ, Vuorikoski S, Sundström JT, Järveläinen HT. Decorin in human colon cancer: localization in vivo and effect on cancer cell behavior in vitro. J Histochem Cytochem. 2015;63:710–20.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature. 1990;346:281–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Zafiropoulos A, Nikitovic D, Katonis P, Tsatsakis A, Karamanos NK, Tzanakakis GN. Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells. Mol Cancer Res. 2008;6:785–94.CrossRefPubMedGoogle Scholar
  25. 25.
    Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, Iozzo RV. Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels. J Biol Chem. 2010;285:42075–85.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Buraschi S, Neill T, Goyal A, Poluzzi C, Smythies J, Owens RT, Schaefer L, Torres A, Iozzo RV. Decorin causes autophagy in endothelial cells via Peg3. Proc Natl Acad Sci U S A. 2013;110:E2582–91.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Neill T, Schaefer L, Iozzo RV. Decorin as a multivalent therapeutic agent against cancer. Adv Drug Deliv Rev. 2016;97:174–85.CrossRefPubMedGoogle Scholar
  28. 28.
    Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, Guzman G, Iozzo RV, Augenlicht LH, Yang W. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis. 2008;29:1435–40.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, Eichstetter I. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci U S A. 1999;96:3092–7.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Cawthorn TR, Moreno JC, Dharsee M, Tran-Thanh D, Ackloo S, Zhu PH, Sardana G, Chen J, Kupchak P, Jacks LM, Miller NA, Youngson BJ, Iakovlev V, Guidos CJ, Vallis KA, Evans KR, McCready D, Leong WL, Done SJ. Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival. PLoS One. 2012;7:e30992.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC, Watson PH. Reduced expression of the small leucine-rich proteoglycans, lumican,and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res. 2003;9:207–14.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Xuan Hong
    • 1
  • Zhaoyang Yang
    • 1
  • Meng Wang
    • 1
  • Li Wang
    • 2
  • Qingyong Xu
    • 2
  1. 1.Department of Medical OncologyHarbin Medical University Cancer HospitalHarbinChina
  2. 2.Department of Radiation OncologyHarbin Medical University Cancer HospitalHarbinChina

Personalised recommendations